Device for occluding a lumen

Information

  • Patent Grant
  • 10058330
  • Patent Number
    10,058,330
  • Date Filed
    Friday, May 11, 2012
    12 years ago
  • Date Issued
    Tuesday, August 28, 2018
    6 years ago
Abstract
One embodiment according to the present invention includes an occlusion device in which the support structure or frame expands circumferentially within the lumen to secure an expansile plug or embolic material. Once in place, the expansile plug or embolic material expands, thereby occluding the target lumen. Another embodiment according to the present invention includes a radially expandable support structure having a closed portion for capturing subsequently delivered embolic material, such as embolic coils. For example, the structure may have a closed portion at its distal end or at its middle (forming an hourglass shape). Additionally, the closed portion may be formed from the support structure itself or from a discrete, second layer that is attached within the support structure.
Description
FIELD OF THE INVENTION

The present invention is directed to devices for occluding lumens within a body and, more particularly, directed to devices employing an expansile frame associated with an expansile plug and methods for use and manufacturing of such devices.


BACKGROUND OF THE INVENTION

It is often necessary to close a blood vessel, lumen, duct, aneurysm, hole, fistula, or appendage, referred to herein collectively as a lumen, within a body. For example, under certain circumstances the optimum treatment for an aneurysm is to occlude the vessel that feeds blood into the lesion. In the neurovascular anatomy, this vessel may be the carotid artery, or in the peripheral vasculature, it may be an iliac artery. Additional examples include: a patent ductus arteriosus (PDA) which shunts blood from the aorta to the pulmonary artery in some newborn babies; a patent foramen ovale (PFO), an open flap in the septum separating the heart's atria; a blood vessel feeding a tumor; an atrial septal defect (ASD), a hole in the septum between the atria; an iliac artery in conjunction with a stent graft and a femoral-femoral bypass operation the closure of which provides treatment of an aortic aneurysm; an atrial appendage, which is a malformation that allows blood clots to collect, which, in turn, may cause a stroke. Furthermore, there are various types of fistula in which organs are improperly connected together such as colovaginal fistula, oromaxillary fistula, and arteriovenous malformation (AVM).


There are numerous devices in the prior art that may be used to close or otherwise occlude these lumens. One such device is a detachable balloon which is inflated in the target lumen with a liquid or polymer, then detached and maintained at or in the target. Another device is a basket-like structure formed of wires that causes clots in the blood flow thereby blocking a blood vessel. Another device is a coil or hydrogel coated coil that is deployed in a lumen. Another device is a self-expanding patch that blocks a PFO or ASD from both sides. Further examples include plugs, beads, or particles made from hydrogel or polyvinyl alcohol (PVA) that may expand upon blood contact and serve to occlude or block a lumen.


There is, however, an ongoing need to provide a more advanced and improved device for occluding lumens that is easier to place, requires fewer steps for deployment, and has a lower tendency to migrate after placement.


SUMMARY OF THE INVENTION

One embodiment according to the present invention includes an occlusion device in which the support structure or frame expands circumferentially within the lumen to secure an expansile plug or embolic material. Once in place, the expansile plug or embolic material expands, thereby occluding the target lumen.


Another embodiment according to the present invention includes a radially expandable support structure having a closed portion for capturing subsequently delivered embolic material, such as embolic coils. For example, the structure may have a closed portion at its distal end or at its middle (forming an hourglass shape). Additionally, the closed portion may be formed from the support structure itself or from a discrete, second layer that is attached within the support structure.


The occlusion devices of the present invention can be useful in multiple medical fields such as radiology, gastroenterology, gynecology, cardiology, neurovascular intervention, and oncology.





BRIEF DESCRIPTION OF THE DRAWINGS

These and other aspects, features, and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which



FIG. 1 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 2 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 3 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 4 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 5 is a plan view of a portion of a device according to one embodiment of the present invention;



FIG. 6 is a side elevation view of a device according to one embodiment of the present invention;



FIG. 7 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 8 is a side elevation view of a portion of a device according to one embodiment of the present invention;



FIG. 9 is a side elevation view of a device according to one embodiment of the present invention;



FIG. 10A is a side elevation view of a device according to one embodiment of the present invention;



FIG. 10B is a side elevation view of a device according to one embodiment of the present invention;



FIG. 11 is a side elevation view of a device according to one embodiment of the present invention;



FIG. 12 is a side elevation view of the device seen in FIG. 11;



FIG. 13 is a side elevation view of a device according to one embodiment of the present invention; and,



FIG. 14 is a side elevation view of a device according to one embodiment of the present invention.





DETAILED DESCRIPTION OF THE EMBODIMENTS

Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.


The embodiments of the present invention are generally directed to lumen occlusion devices having an expandable framework. As described in more detail below, the framework may have an attached, expansile plug or may be filled with embolic material after deployment.



FIGS. 1-5 illustrate a device 10 according to the present invention, which employs one or more expandable plug 12 associated with a frame or support structure 14. The frame 14 is preferably formed of a single wire 16 braided or woven into a generally tubular form but can also be formed by weaving multiple, discrete wires or laser cutting a tube. In one example, the frame 14 has an external diameter of approximately 4.5 millimeters and a length of approximately 15 millimeters. The wire 16 is preferably formed of NiTi or nickel-titanium alloy, also known as Nitinol, having a diameter of approximately 0.00325 inches.


The frame 14 has a proximal end portion 18 and a distal end portion 20 that are outwardly flared. Alternatively stated, the proximal end portion 18 and the distal end portion 20 employ projecting elements 22 extending radially outward. In certain embodiments, the projecting elements 22 take the form of loops, hooks, protuberances, or staples, which tend to increase the friction between the frame and the lumen. These projecting elements 22 tend to hold the frame 14 in place in conjunction with the frame's 14 radial force. This feature is especially useful when the area or lumen to be obstructed is relatively short, which reduces the aggregate radial force of the frame 14 compared to a longer lumen, or where there is high flow such as an iliac or carotid artery.


In certain embodiments, a variety of radiopaque markers such as marker bands, coils, and plating, not shown, are connected to the frame 14. For example, markers can be located at the ends of the projecting elements 22, near the plug 12, and/or along a length of the frame 14 to assist the operator with visualization, guidance and delivery of the device 10 during deployment.


Formation of the relaxed or minimum energy state configuration of shape memory structures such as the device 10 described herein are well known in the art. For example, the relaxed or minimum energy state configuration of the frame 14 is formed by weaving, winding, or otherwise manipulating the wire 16 about a fixture. Once the desired form is achieved for the frame 14, the frame 14 is subjected to a heat treatment. For example, the frame 14 is maintained at a temperature of about 500 degrees Celsius to about 1000 degrees Celsius for approximately 30 to 90 minutes. Following the heat treatment, the frame 14 is cooled to room temperature and ultrasonically cleaned. The resultant secondary configuration is thereby made permanent and becomes the relaxed or minimum energy state configuration of the device 10.


In one embodiment, the frame 14 is formed of a plurality of the same or a combination of different wires 18. For example, the wire 16 may be formed of Nitinol, steel, chromium-cobalt alloy, and/or platinum, and/or of polymers such as Teflon, polyethylene terephthalate (PET), or polyether ether ketone (PEEK).


In one embodiment, the frame 14 can be any of the stents seen in U.S. application Ser. No. 13/003,277 filed Jan. 7, 2011 and U.S. application Ser. No. 13/311,430 filed Dec. 5, 2011, the contents of which are hereby incorporated by reference.


The plug 12 is formed of, for example, hydrogel or other similar expansile material such as PVA or hydrogel foam. As shown in FIGS. 1-5, the plug 12 is preferably formed in the shape of a cylinder that expands after being introduced into a patient. In a reduced or non-expanded state, the plug 12 preferably has a diameter of approximately 1 millimeter and a length of approximately 7 millimeters. In an expanded, unrestricted state (for example, caused by exposure of the plug 12 to water or blood), the plug 12 preferably has a diameter of approximately 4 millimeters and a length of approximately 14 millimeters.


The plug 12 can be constructed from a variety of known polymeric materials including, for example, biocompatible, macroporous or microporous, hydrophilic or hydrophobic hydrogel foam materials. Suitable materials are described in U.S. Pat. No. 6,165,193 to Greene Jr. et al. and U.S. Pat. No. 6,878,384 to Cruise et al., each of which is hereby incorporated by reference. The plug 12 may also comprise polymers such as polyvinyl alcohol foams as described in U.S. Pat. No. 5,823,198 to Jones et al., which is also incorporated herein by reference.


In another embodiment of the present invention, the plug 12 is made of a biocompatible, macroporous, hydrophilic hydrogel foam material, in particular a water-swellable foam matrix formed as a macroporous solid comprising a foam stabilizing agent and a polymer or copolymer of a free radical polymerizable hydrophilic olefin monomer cross-linked with up to about 10% by weight of a multiolefin-functional cross-linking agent. A suitable material of this type is described in U.S. Pat. No. 5,750,585 to Park et al., the disclosure of which is incorporated herein by reference. Another suitable material is a porous hydrated polyvinyl alcohol foam (PAF) gel prepared from a polyvinyl alcohol solution in a mixed solvent consisting of water and a water-miscible organic solvent, as described, for example, in U.S. Pat. No. 4,663,358 to Hyon et al., the disclosure of which is incorporated herein by reference. Still another suitable material is PHEMA, as discussed in U.S. Pat. No. 4,663,358 to Hyon et al., “Hydrolysed Microspheres from Cross-Linked Polymethyl Methacrylate”, J. Neuroradiol., Vol. 18, pp. 61-69 (1991), both of which are hereby incorporated by reference.


It may be desirable to reduce the size of the plug 12 for the purpose of performing percutaneous procedures. This may be done mechanically by using a fixture to compress the plug, chemically by dehydrating the polymer with an agent such as alcohol, or through a combination of these methods. I


In certain embodiments of the present invention, the plug 12 may incorporate radiopaque elements, for example, iodine or tantalum powder, mixed into the material forming the plug 12 during manufacturing to help visualize the location of the plug 12 and the device 10 before and after deployment.


The plug 12 is preferably associated with or otherwise attached to the frame 14 by a thread 24. The thread 24 is formed of, for example, polyethylene terephthalate (PET) having a diameter of approximately 0.0009 inches. One end of the thread 24 is skewered or otherwise passed through a portion of the plug 12 and around the wire 16 of the frame 14 and then fixed to a second end of the thread 24 so as to form a loop. A plurality of threads 24 may also be employed to secure the plug 12 to the frame 14 at the same or at different locations along a dimension of the frame 14.


In certain embodiments, the plug 12 is associated with the frame 14 by employing a thread 24 formed of polypropylene or olefin elastomer such as Engage. Still in other embodiments, the plug 12 is associated with the frame 14 by mechanical methods such as: constructing the frame 14 in the shape of a cage or basket that holds the plug 12 within; directly skewering an element of the frame 14, such as a portion of the wire 16, through the plug 12; gluing the plug to the frame 14; incorporating mechanical grasping elements into the frame 14 to hold the plug 12; or using heat-shrinkable plastic to hold the plug 12 to the frame 14.


After the frame 14 and plug 12 have been associated, the device 10 can be loaded into a delivery device such as a catheter or sheath. In a more specific example, the device 10 can be compressed on an inner pusher member that is located within a retractable sheath. In one example, the delivery device has a size of about 4 French for delivery into a lumen or vessel between about 2-4 millimeters in diameter.



FIG. 6 illustrates another embodiment of a device 100 having a generally “hourglass” shaped side-profile. More specifically, the device 100 includes a frame 102, preferably composed of a single wire that forms a spiral or a substantially planar helix. Loops of the frame 102 have a generally smaller diameter at a middle region of the frame 102 and increase in diameter towards the distal and proximal ends of the frame 102.


One or more plugs 12 are attached at the narrow, center portion of the frame 102 as described in previous embodiments, for example by employing threads 24. Alternatively, one or more plugs 12 may be anchored to the frame 102 by skewering the plugs 12 with the frame 102. Radiopaque markers, not shown, may also be employed as previously described regarding the device 10. The device 100 is at least partially linearized (i.e., the coil shape is at least partially uncoiled into a generally linear shape) for delivery via a delivery catheter and deployed.


The device 100 is especially useful for closing lumens that have large diameters relative to their lengths and lumens in which a treatment device is subjected to forces from multiple directions. Examples of these types of lumens are ASD, PFO, and PDA's. The device 100 is useful in occluding these lumens because the distal end of the frame 102 can be placed on one side of the lumen (i.e. in the atrium or pulmonary artery), the plug 12 positioned substantially within the lumen, and the proximal end on the other side of the lumen. Since the frame 102 tends to revert to its original substantially helical configuration, it tends to exert force on both sides of the septum or ductus, thus sandwiching the plug in the lumen.


In another embodiment of the present invention, as shown in FIG. 7, a device 40 employs a frame 44 that is generally similar to the previously described frame 14, except that a distal end portion 46 and a proximal end portion 48 of the frame 44 are closed such that an interior of the frame is at least partially closed-off. This configuration prevents the plug 12 from migrating in one or both directions in the event that the thread 24 holding the plug 12 in place breaks or if the hydrated plug 12 could not be anchored by the thread 24 alone.


In another embodiment, as shown in FIG. 8, the device 42 employs a frame 44 as previously described, except that the upstream, proximal end 50 remains open and preferably at least partially flared. In this configuration, the plug 12 may, but need not be, attached to the frame by a thread 24. As the downstream or distal end 46 of the frame 44 is closed, the plug 12 is prevented from migrating downstream. In such a configuration, the plug 12 may be delivered into the frame as a separate step during deployment of the device.


In yet another embodiment, one or both ends of the frame are at least partially closed or covered with, for example, a mesh, crossing or interwoven threads, or fabric. This covering can be attached over either open or closed ends of the frame and prevents the plug 12 from migrating away from the frame and target.


In one embodiment, as shown in FIG. 9, a device 60 includes a frame 62 comprising a twisted wire that forms a corkscrew shape. Generally, the twisted wire of the frame 62 can form uniform-sized loops so as to maintain a relatively uniform or linear shape. However, the loops of the frame 62 may also have varying sizes so as to form a triangular, conical, or hourglass shape. The plug 12 is attached to the frame 62 directly by skewering the wire or coil through one or more plugs 12 or by using the thread 24 or wire to tether the plug(s) 12 to the frame. Preferably, the frame 62 is sized to have a diameter or height that will be approximately the same size or somewhat larger than the target lumen. The device 60 can be loaded into a delivery catheter by compressing it into a linear configuration (e.g., by physically decreasing the size of the loops) within a lumen of the catheter or onto a delivery pusher. As the device 60 is pushed or released into the target lumen, it expands to its relaxed, twisted configuration.



FIGS. 10A and 10B illustrate yet another embodiment of an occlusion device 110 that comprises a plug 12 through which a plurality of filaments or wires 114 pass through. The plug 12 is formed of, for example, hydrogel or other similar expansile material such as PVA or foam. The wires 114 are passed through the plug 12 along an approximate central axis 118 of the device 110. The wires 114 are configured (e.g., pre-shaped) to curve or bend away from each other in a radial direction relative to the central axis 118. In one example, the wires 114 bend or extend away from the approximate central axis 118 for a length of approximately 6 millimeters.


The wires 114 can be radially oriented in a uniform spacing, such as approximately 120 degrees apart, or in any variety of symmetrical and asymmetrical, non-uniform spacing, such as 100, 130, 130 degrees. In one example configuration, the wires 114 are composed of a shape memory material such as Nitinol, have a diameter of about 0.003 inches, and have ends that are capped with radiopaque markers 120. Alternatively, the wires 114 may be formed by laser cutting a hypotube to the desired dimensions of the wire 114.


The device 110 is particularly useful for closing a PDA. The device 110 can be collapsed into a delivery system and delivered to a target site by conventional means. In one example, the plug 12 expands to a dimension of about 0.185 inches after deployment and closes off or otherwise seals the target site (e.g., a PDA). The expanded and radially curved wires 114 are preferably deployed on either side of the defect and thereby provide support for the plug 12 so as to prevent migration. It should be noted that the device 110 may include any number of wires 114, but preferably between at least 2 and 20 wires, and more preferably at least 3-6 wires. Advantageously, the device 110 is relatively simple to construct and tends to have a smaller delivery profile as compared with many other device shapes.


While the previously described embodiments have included the use of an expandable plug 12, it is also possible to use one or more of these devices without a plug 12. More specifically, a material can be added upstream or adjacent to the deployed device so as to cause the blockage. For example, one or more embolic coils (which may or may not include an expandable material such as hydrogel), can be delivered within the deployed and expanded device.



FIGS. 11 and 12 illustrate one such example of an intravascular self-expanding stent-type device 140 that can be filled with embolic materials such as embolic coils 168. Other embolic material, such as a liquid embolic material (e.g. Onyx), embolizing beads (e.g. Embosphere), or other embolizing agents can also be used. The device 140 comprises a frame or a support structure 142 that is circumferentially open on both a distal end 144 and a proximal end 146, as described above regarding frame 14. A cinched center section 148 creates an embolic material capture region that obstructs the central lumen of the device 140, thereby acting as a stable barrier for subsequent embolic material delivery. The center 148 can be woven together or fastened by a thread, wire, clip or other fastening member and allows for a decreased diameter and controlled deployment.


Once the device 142 is deployed at a target occlusion location, a second delivery catheter 141 (or possibly the same delivery catheter) is advanced to the proximal end 146 of the device 142 and embolic material is deployed into the proximal half of the device 142. In this example, the embolic material is one or more embolic coils 168. These embolic coils 168 may include an expansile coating (such as hydrogel) that expands within a patient's blood or may include expansile material that is separate from the coils 168. In this respect, half of the device 142 is filled with material, thereby occluding most of the blood flow through the lumen 152. Over time, this occlusion will likely become completely blocked by expansion of any expansile coating on the embolic coils 168, clotting of the blood and/or tissue growth over the embolic coils 168.



FIG. 13 illustrates an intravascular self-expanding stent-type device 160 that is generally similar to the previously described device 42 of FIG. 8, but without the plug 12. The device 160 comprises a frame 162 that facilitates lumen occlusion when used in conjunction with an embolic coil 168 or other embolic materials. Only a downstream or distal end 164 of the frame 162 is at least partially closed and a proximal end 166 is open, as described above regarding the frame 14.


As with the previous embodiment, the device 162 is delivered to a desired occlusion point in a lumen 152. Next, the distal end of the delivery catheter 141 is positioned adjacent or even partially inside of the framework 162 and the embolic coils 168 are deployed within the device 160. Since the downstream or distal end 164 of the frame 162 is closed to act as a stable barrier, the embolic coil 168 is prevented from migrating downstream through the lumen 152, thus occluding the lumen 152. Again, other embolic materials, such as hydrogel, may be used in conjunction with device 160 and embolic coils 168.


Alternately, both ends of the device 162 may be closed and the embolic material, such as embolic coils 168 can be delivered inside a cavity of the device, through apertures in the weaving. For example, an embolic coil deliver catheter can be inserted through an aperture created by its woven wires and the embolic coil can be advance into the device 162.



FIG. 14 illustrates a dual-layer stent device 170 that includes an outer, anchoring stent layer 172 and an inner, occluding stent layer 180. Generally, this dual-layer stent device 170 is similar to and can be constructed according to the teachings in U.S. application Ser. No. 13/003,277 filed Jan. 7, 2011 and U.S. application Ser. No. 13/311,430 filed Dec. 5, 2011, the contents of which are incorporated herein by reference. The outer stent layer 172 expands against the lumen 152 to anchor the device 170 against the lumen 152 while the inner stent layer 180 is cinched near a middle location 178 to form an hourglass shape. Alternately, the inner stent layer 180 can be cinched at its distal end to create a shape similar to that of device 160 in FIG. 13.


Preferably, occluding material, such as embolic coils 168 can be delivered into the proximal end 176 of the device 170 to occlude the lumen 152. The inner stent layer 180 may be coated in an expansile material, such as hydrogel, in addition to or in place of the discretely-added occluding material.


The outer, anchoring stent layer 172 is preferably composed of one or more wires having a larger diameter than those composing the inner, occluding stent layer 180. Additionally, the outer layer 172 can be woven to have apertures that are larger than those of the inner stent layer 180, when both layers are in an expanded configuration. In this respect, the outer layer 172 can provide relatively more radially outward force for anchoring while the inner layer 180 can provide a relatively finer-woven occlusive barrier.


Preferably, the inner stent layer 180 is connected to the outer stent layer 172 at its proximal end and optionally at its distal end. Additionally, the inner stent layer 180 can be located near the outer stent layer's proximal end 176, distal end 174, middle, or any positions therebetween.


The device 170 has several advantages compared to prior art lumen obstruction devices that occlude a lumen by preventing dislodgement of embolization coils, The present invention allows partial deployment of re-sheathing due to its attachment mechanism, allowing for a more controlled placement of the device. Further, the present invention can be used with much smaller catheters, conceivably down to 1.7 French compared to a 5 French or greater sized catheter. This allows the present invention to navigate more tortuous and distal lumens, thereby being able to treat a wider range of patients. Additionally, this allows the same catheter to be used to deliver both the device and the embolic coils and materials. Further, the present invention minimizes any trauma imposed on the lumen wall by using a self-expanding radial force tuned for the artery size.


The previously described device, such as 140, 160, and 170, can be made with a variety of materials including, but not limited to bioactive, thrombogenic, hydrogel, or other therapeutic coatings. Further, these devices can be made in a variety of different sizes and lengths and can be cinched or enclosed at any location along the length of the stent. To improve clinical outcomes, the device can be coated with, for example, bioactive or hydrogel coatings. The device can be used with varying porosities to provide full or partial flow occlusion to limit the amount of embolic materials required to sufficiently occlude a lumen.


Delivery of the above described devices can be accomplished using various delivery systems. For example, the device can be delivered by pushing the device through a catheter or sheath with a specialized pusher or a guidewire by attaching one or both ends of the device to a delivery pusher that holds the device so that it can be positioned and repositioned within the lumen. The device is then selectively detached from the delivery system by, for example, mechanically, thermally, hydraulically, or electrolytically severing an attachment member associating the device and the delivery system.


In one embodiment, the device incorporates at least one radiopaque marker band positioned at one end of the device. The marker is configured to interlock to a mating element on a delivery pusher. The user can partially deploy and retrieve the device using the interlock to pull back on the device. Release of the device from the delivery system is, for example, accomplished by pushing most of the implant out of the delivery catheter and/or retracting the delivery catheter to expose the interlock release(s).


In another embodiment, a monofilament is wrapped through the proximal end of the device and then attached to a delivery pusher incorporating a heater that can be activated by electrical current. The user can fully or partially deploy the device and then reposition or recover the device if needed. When the device is in the desired location, the user activates the heater thereby causing the monofilament to break from and release the device.


In yet another embodiment, one end of the device incorporates an atraumatic tip while the other end is soldered to a delivery pusher. The user can deploy and reposition the device as needed, and then pass a current through the delivery pusher. The current causes the solder to corrode at an accelerated rate in the patient's blood and to release the end of the device that was soldered to the pusher.


Alternatively, the end of the device incorporates a coupling element such as a tube of radiopaque material that is configured to allow a heat-severable thread having two ends to pass through the coupling. One end of the thread is tied to the device and the other end of the thread is passed through a heater incorporated into the end of a delivery pusher. The device is detached by the user as previously described.


In another embodiment, the delivery system includes a sheath disposed over a pusher member. A stent device is compressed over a distal end of the pusher and the sheath is placed over the stent. In this respect, the stent is maintained in place, in part, via frictional forces. Additional details of such a delivery system can be found in U.S. application Ser. No. 13/003,277 filed Jan. 7, 2011 and U.S. application Ser. No. 13/311,430 filed Dec. 5, 2011, both of which were previously incorporated by reference in this specification.


The present device and method has several advantages over the prior art. In comparison to prior art detachable balloons, the device of the present invention is easier to place, requires fewer steps to deploy, and has a lower tendency to migrate after placement if, for example, a balloon-based device starts to leak over time.


Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.

Claims
  • 1. An occlusion device comprising: a stent comprising a woven tubular support structure having a compressed configuration and an expanded configuration, wherein said woven tubular support structure is configured to self-expand to said expanded configuration, forming a plurality of radially projecting loops on a proximal and distal end of said stent and forming an elongated passage therethrough terminating with a proximal opening and a distal opening;a plug comprising hydrogel and having a compressed dehydrated state and an expanded hydrated state and self-expanding from a compressed configuration due to the presence of liquid to an expanded configuration the plug fixed within said tubular support structure, said plug compressed from an initial size prior to insertion within said stent and thus being of substantially smaller diameter than said woven tubular support structure when said tubular support structure is in said expanded configuration, said plug further utilizing a powdered visualization agent; and,a thread having a first end and a second end, and being skewered through substantially an entire length of said plug and around a wire of said woven tubular structure; said first end being fixed to said second end to form a loop and so as to fix said plug to said woven tubular structure in both said compressed dehydrated state and in said expanded hydrated state and so as to maintain said thread from extending beyond said proximal opening and said distal opening.
  • 2. An occlusion device comprising: a stent comprising a woven tubular frame structure forming a passage therethrough; said tubular frame structure having a compressed configuration and an expanded configuration, and a plurality of radially projecting loops at a proximal and distal end of said stent; anda plug solely comprising expansile material in the form of hydrogel, having a compressed dehydrated state and an expanded, hydrated state; the presence of a liquid causing said plug to expand, said plug compressed from an initial size prior to insertion within said stent and thus being of substantially smaller diameter than said woven tubular support structure when said tubular support structure is in said expanded configuration, said plug further utilizing a powdered visualization agent; and,a thread having a first end and a second end passing around a wire forming said woven tubular frame structure and fixing said plug within said passage in said compressed dehydrated state and in said expanded hydrated state; said thread being skewered through substantially an entire length of said plug and said first end being fixed to said second end to form a loop and said thread only extending along a portion of said woven tubular frame structure.
  • 3. The occlusion device of claim 2, wherein said tubular frame structure is formed from a single wire.
RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent Application Ser. No. 61/485,065 filed May 11, 2011 entitled Device for Occluding A Lumen, the entirety of which is incorporated by reference herein.

US Referenced Citations (277)
Number Name Date Kind
3868956 Alfidi Mar 1975 A
4130904 Whalen Dec 1978 A
4140126 Choudhury Feb 1979 A
4286341 Greer et al. Sep 1981 A
4512338 Balko et al. Apr 1985 A
4553545 Maass et al. Nov 1985 A
4562596 Kornberg Jan 1986 A
4577631 Kreamer Mar 1986 A
4655771 Wallsten Apr 1987 A
4663358 Hyon et al. May 1987 A
4733665 Palmaz Mar 1988 A
4734097 Tanabe et al. Mar 1988 A
4740207 Kreamer Apr 1988 A
4768507 Fischell et al. Sep 1988 A
4800882 Gianturco Jan 1989 A
4852568 Kensey Aug 1989 A
4856516 Hillstead Aug 1989 A
4941870 Okada et al. Jul 1990 A
4990582 Salamone Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
5015253 MacGregor May 1991 A
5019090 Pinchuk May 1991 A
5026377 Burton et al. Jun 1991 A
5035706 Giantureo et al. Jul 1991 A
5041126 Gianturco Aug 1991 A
5041292 Feijen Aug 1991 A
5078726 Kreamer Jan 1992 A
5084065 Weldon et al. Jan 1992 A
5116365 Hillstead May 1992 A
5133731 Butler et al. Jul 1992 A
5135536 Hillstead Aug 1992 A
5158548 Lau et al. Oct 1992 A
5162430 Rhee et al. Nov 1992 A
5171262 MacGregor Dec 1992 A
5192297 Hull Mar 1993 A
5197978 Hess Mar 1993 A
5226911 Chee et al. Jul 1993 A
5234456 Silvestrini Aug 1993 A
5256146 Andrews Oct 1993 A
5258042 Mehta Nov 1993 A
5304200 Spaulding Apr 1994 A
5312415 Palermo May 1994 A
5314444 Gianturco May 1994 A
5342300 Stefanadis Aug 1994 A
5382259 Phelps et al. Jan 1995 A
5382260 Dormandy, Jr. et al. Jan 1995 A
5383887 Nadal Jan 1995 A
5389106 Tower Feb 1995 A
5395390 Simon et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5410016 Hubbell et al. Apr 1995 A
5415664 Pinchuk May 1995 A
D359802 Fontaine Jun 1995 S
5433723 Lindenberg et al. Jul 1995 A
5464449 Fogarty Nov 1995 A
5476472 Dormandy, Jr. et al. Dec 1995 A
5476505 Limon Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484449 Amundson et al. Jan 1996 A
5514379 Weissleder et al. May 1996 A
5514380 Song et al. May 1996 A
5536274 Neuss Jul 1996 A
5540701 Erlich Jul 1996 A
5554190 Draenert Sep 1996 A
5558633 Phipps et al. Sep 1996 A
5578074 Mirigian Nov 1996 A
5582619 Ken Dec 1996 A
5607445 Summers Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609628 Keranen Mar 1997 A
5609629 Fearnot et al. Mar 1997 A
5613981 Boyle et al. Mar 1997 A
5624461 Mariant Apr 1997 A
5630829 Lauterjung May 1997 A
5645558 Horton Jul 1997 A
5658308 Snyder Aug 1997 A
5674241 Bley et al. Oct 1997 A
5674276 Andersen et al. Oct 1997 A
5674295 Ray et al. Oct 1997 A
5702418 Ravenscroft Dec 1997 A
5716410 Wang et al. Feb 1998 A
5718711 Berenstein et al. Feb 1998 A
5741325 Chaikof et al. Apr 1998 A
5749894 Engelson May 1998 A
5750585 Park et al. May 1998 A
5769882 Fogarty et al. Jun 1998 A
5785679 Abolfathi et al. Jul 1998 A
5785965 Pratt et al. Jul 1998 A
5800454 Jacobsen et al. Sep 1998 A
5823198 Jones et al. Oct 1998 A
5843089 Sahatjian et al. Dec 1998 A
5898062 Allcock et al. Apr 1999 A
5911717 Jacobsen et al. Jun 1999 A
5911731 Pham et al. Jun 1999 A
5919224 Thompson et al. Jul 1999 A
5935148 Villar et al. Aug 1999 A
5941249 Maynard Aug 1999 A
5951599 McCrory Sep 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980550 Eder Nov 1999 A
5980554 Lenker et al. Nov 1999 A
5990237 Bentley et al. Nov 1999 A
6015431 Thornton et al. Jan 2000 A
6036720 Abrams et al. Mar 2000 A
6053940 Wijay Apr 2000 A
6060534 Ronan et al. May 2000 A
6063070 Eder et al. May 2000 A
6063111 Hieshima et al. May 2000 A
6086577 Ken et al. Jul 2000 A
6090911 Petka et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6113629 Ken Sep 2000 A
6120847 Yang et al. Sep 2000 A
6140127 Sprague Oct 2000 A
6143022 Shull et al. Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6165194 Denardo et al. Dec 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6176240 Nikolchev et al. Jan 2001 B1
6177095 Sawhney et al. Jan 2001 B1
6184266 Ronan et al. Feb 2001 B1
6187370 Dinh et al. Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6201065 Pathak et al. Mar 2001 B1
6221099 Andersen et al. Apr 2001 B1
6224892 Searle May 2001 B1
6231597 Deem May 2001 B1
6261305 Marotta et al. Jul 2001 B1
6264695 Stoy Jul 2001 B1
6268161 Han et al. Jul 2001 B1
6273908 Ndondo-Lay Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6287318 Villar Sep 2001 B1
6287333 Appling et al. Sep 2001 B1
6309367 Boock Oct 2001 B1
6360129 Ley et al. Mar 2002 B1
6364893 Sahatjian et al. Apr 2002 B1
6383174 Eder May 2002 B1
6398808 Palasis Jun 2002 B1
6419686 McLeod et al. Jul 2002 B1
6551303 Van Tassel et al. Apr 2003 B1
6554849 Jones et al. Apr 2003 B1
6569179 Teoh et al. May 2003 B2
6569190 Whalen, II et al. May 2003 B2
6582460 Cryer Jun 2003 B1
6596296 Nelson et al. Jul 2003 B1
6605111 Bose et al. Aug 2003 B2
6605294 Sawhney Aug 2003 B2
6613073 White et al. Sep 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6663607 Slaikeu et al. Dec 2003 B2
6712836 Berg et al. Mar 2004 B1
6716445 Won et al. Apr 2004 B2
6723108 Jones et al. Apr 2004 B1
6746468 Sepetka et al. Jun 2004 B1
6748953 Sherry et al. Jun 2004 B2
6786876 Cox Sep 2004 B2
6811560 Jones et al. Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6878384 Cruise et al. Apr 2005 B2
6932833 Sandoval et al. Aug 2005 B1
7018403 Pienknagura Mar 2006 B1
7037331 Mitelberg et al. May 2006 B2
7195648 Jones et al. Mar 2007 B2
7241301 Thramann Jul 2007 B2
7300661 Henson et al. Nov 2007 B2
7311726 Mitelberg et al. Dec 2007 B2
7361367 Henson et al. Apr 2008 B2
7371228 Chu et al. May 2008 B2
7396540 Chu et al. Jul 2008 B2
7442382 Henson et al. Oct 2008 B2
7481821 Fogarty Jan 2009 B2
7517361 Ravenscroft Apr 2009 B1
7530988 Evans et al. May 2009 B2
7569066 Gerberding et al. Aug 2009 B2
7572288 Cox Aug 2009 B2
7582109 Delegge Sep 2009 B2
7666220 Evans et al. Feb 2010 B2
7790273 Lee et al. Sep 2010 B2
7815661 Mirizzi et al. Oct 2010 B2
7862538 Sawhney et al. Jan 2011 B2
7951448 Lee et al. May 2011 B2
7959676 Thramann et al. Jun 2011 B2
8048145 Evans et al. Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8105352 Egnelov Jan 2012 B2
8182525 Herbowy et al. May 2012 B2
8231666 Kim et al. Jul 2012 B2
8231890 Cruise et al. Jul 2012 B2
8252040 Cox Aug 2012 B2
8262686 Fogarty Sep 2012 B2
8317799 Schon Nov 2012 B2
8333798 Gandhi et al. Dec 2012 B2
8465779 Cruise et al. Jun 2013 B2
8486046 Hayman et al. Jul 2013 B2
8535367 Kim et al. Sep 2013 B2
8562341 Luebke Oct 2013 B2
8562636 Fogarty Oct 2013 B2
8562643 Tekulve et al. Oct 2013 B2
8562662 Kim et al. Oct 2013 B2
8585723 Nardone et al. Nov 2013 B2
8597674 Chu et al. Dec 2013 B2
8636764 Miles et al. Jan 2014 B2
8647377 Kim et al. Feb 2014 B2
20010000188 Lenker et al. Apr 2001 A1
20010000797 Mazzocchi et al. May 2001 A1
20010012961 Deem Aug 2001 A1
20010025195 Shaolian et al. Sep 2001 A1
20010047202 Slaikeu Nov 2001 A1
20020013618 Marotta Jan 2002 A1
20020026228 Schauerte Feb 2002 A1
20020026232 Marotta Feb 2002 A1
20020049495 Kutryk Apr 2002 A1
20020052648 Mcguckin May 2002 A1
20020123789 Francis Sep 2002 A1
20020143349 Gifford et al. Oct 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20030004531 Jones Jan 2003 A1
20030018294 Cox Jan 2003 A1
20030023190 Cox Jan 2003 A1
20030055451 Jones Mar 2003 A1
20030120300 Porter Jun 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030135267 Solem Jul 2003 A1
20030139802 Wulfman Jul 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030171739 Murphy Sep 2003 A1
20040034386 Fulton Feb 2004 A1
20040044351 Searle Mar 2004 A1
20040087998 Lee et al. May 2004 A1
20040093076 White May 2004 A1
20040098027 Teoh et al. May 2004 A1
20040106945 Thramann Jun 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040172056 Guterman Sep 2004 A1
20040186562 Cox Sep 2004 A1
20040193206 Gerberding Sep 2004 A1
20050033409 Burke Feb 2005 A1
20050090856 Porter Apr 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060009798 Callister et al. Jan 2006 A1
20060052820 Haig Mar 2006 A1
20060122685 Bonsignore et al. Jun 2006 A1
20060206201 Garcia et al. Sep 2006 A1
20070078479 Belenkaya et al. Apr 2007 A1
20070148243 Bates Jun 2007 A1
20070179590 Lu et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070227544 Swann et al. Oct 2007 A1
20070276465 Mongrain Nov 2007 A1
20070276470 Tenne Nov 2007 A1
20070299464 Cruise et al. Dec 2007 A1
20080109063 Hancock et al. May 2008 A1
20080208167 Stankus Aug 2008 A1
20080221671 Chouinard et al. Sep 2008 A1
20090056722 Swann Mar 2009 A1
20090099643 Hyodoh et al. Apr 2009 A1
20090177221 Kramann Jul 2009 A1
20090177264 Ravenscroft Jul 2009 A1
20090182371 Clausen et al. Jul 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090232869 Greene, Jr. Sep 2009 A1
20090254176 Butera Oct 2009 A1
20090287145 Cragg et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090287300 Dave et al. Nov 2009 A1
20100262177 Frigstad et al. Oct 2010 A1
20110066221 White et al. Mar 2011 A1
20110245802 Hayman et al. Oct 2011 A1
20120095501 Nardone et al. Apr 2012 A1
20120101519 Hill et al. Apr 2012 A1
20120118445 Luebke May 2012 A1
20120271348 Tekulve Oct 2012 A1
20120272526 Luebke Nov 2012 A1
Foreign Referenced Citations (56)
Number Date Country
0107055 May 1984 EP
0441516 Aug 1991 EP
0518704 Dec 1992 EP
0627201 Dec 1994 EP
0664104 Jul 1995 EP
0717969 Jun 1996 EP
1266631 Dec 2002 EP
1691881 May 2005 EP
1732467 Dec 2006 EP
2105110 Sep 2009 EP
2139898 Nov 1984 GB
WO1989011257 Nov 1989 WO
WO1992014408 Aug 1992 WO
WO1994016629 Aug 1994 WO
WO1995018585 Jul 1995 WO
WO1995032018 Nov 1995 WO
WO1997042910 Nov 1997 WO
WO1998004198 Feb 1998 WO
WO1998050102 Nov 1998 WO
WO1998058590 Dec 1998 WO
WO1999002092 Jan 1999 WO
WO1999005977 Feb 1999 WO
WO1999007293 Feb 1999 WO
WO1999059479 Nov 1999 WO
WO1999062429 Dec 1999 WO
WO1999062432 Dec 1999 WO
WO1999065397 Dec 1999 WO
WO2000004845 Feb 2000 WO
WO2000007524 Feb 2000 WO
WO2000013593 Mar 2000 WO
WO2000018321 Apr 2000 WO
WO2000027292 May 2000 WO
WO2000032112 Jun 2000 WO
WO2000044306 Aug 2000 WO
WO2000056247 Sep 2000 WO
WO2000057818 Oct 2000 WO
WO2000062711 Oct 2000 WO
WO2000074577 Dec 2000 WO
WO2001001890 Jan 2001 WO
WO2001003607 Jan 2001 WO
WO2001037892 May 2001 WO
WO2001041676 Jun 2001 WO
WO2001093780 Dec 2001 WO
WO2002005731 Jan 2002 WO
WO2002080782 Oct 2002 WO
WO2002087472 Nov 2002 WO
WO2003077984 Sep 2003 WO
WO2006081407 Aug 2006 WO
WO2007028452 Mar 2007 WO
WO2007062661 Jun 2007 WO
WO2008115922 Sep 2008 WO
WO2009003049 Dec 2008 WO
WO2009096991 Aug 2009 WO
WO2009132141 Oct 2009 WO
WO2011084536 Jul 2011 WO
WO2013184595 Dec 2013 WO
Non-Patent Literature Citations (19)
Entry
WIPO, International Preliminary Examining Authority (U.S. Patent and Trademark Office), International Preliminary Report on Patentability dated Nov. 21, 2013 in International Patent Application No. PCT/US2012/037621, 7 pages.
Balt Extrusion, Montmorency, Francy, “LEO+,” Intracranial self expandable stent and delivery system, product page.
WIPO, U.S. International Search Authority, International Search Report and Written Opinion dated Oct. 22, 2012 in International Patent Application No. PCT/US2012/037621, 10 pages.
WIPO, U.S. International Search Authority, International Search Report and Written Opinion dated Mar. 7, 2011 in International Patent Application No. PCT/US2010/061627, 9 pages.
Han, Y.M. et al., “Flared Polyurethane-covered Self-expandable Nitinol Stent for Malignant Biliary Obstruction,” J Vase Interv Radiol, Oct. 2003; 14 (10): pp. 1291-1301.
Lieber, B.B. et al., “Alteration of Hemodynamics in Aneurysm Models by Stenting. Influence of Stent Porosity,” Annals of Biomedical Engineering, 1997, vol. 25, pp. 460-469.
Duprat G. Jr., et al., “Self Expanding Evaluation”, Radiology 1987; 162: 469-472.
Guglielmi G., et al., “Electrothrombosis of Results”, J. Neurosurg. 1991; 75: 1-7.
Guglielmi G., et al., “Electrothrombosis of saccular aneurysms via endovascular approach”, J. Neurosurg. 1991; 75: 8-14.
Hieshima G. B. et al., “A Detachable Occlusion”, Radiology 1981; 138: 227-228.
Paper No. 199, American Society of Neuroradiology, 29th Annual Meeting, Washington, D.C., Jun. 9-14, 1991.
Paper No. 200, American Society of Neuroradiology, 29th Annual Meeting, Washington, D.C., Jun. 9-14, 1991.
Romodanov A. P., et al., Intravascular Occlusion Catheter, In Advances & Technical Standards, vol. 9, 1982; 25 49.
Serbinenko F. A. “Balloon Catheterization and Cerebral Vessels”, J. Neurosurg. 1974; 41: 125-145.
Sigwart V., et al., Intravascular Angioplasty, N. England J. Med., 1987; 316: 701 706.
Strecker E. P., “Flexible, Balloon Results”, Radiology 1988; 169: 388.
Ahuja, A.A., Hergenrother, R. W., Strother, C.M., Rappe, A.A., Cooper, S.L., and Graves, V.B., “Platinum Coil Coatings to Increase Thrombogenicity: A Preliminary Study in Rabbits,” AJNR 14:794-798, Jul./Aug. 1993.
Dawson, R., M.D., Krisht, A., M.D., Barrow, D., M.D., Joseph, G., M.D., Shengelaia, G., M.D., and Bonner, G., M.B.A., “Treatment of Experimental Aneurysms Using Collagen-Coated Microcoils,” Neurosurgery, 36:133-140, 1995.
Vinuela, F., M.D., Duckwiler, G., M.D., and Mawad, M., M.D., “Guglielmi Detachable Coil Emoblization of Acute Intracranial Aneurysm: Perioperative Anatomical and Clinical Outcome in 403 Patients,” J. Neurosurg 86:475-482, 1997.
Related Publications (1)
Number Date Country
20120316597 A1 Dec 2012 US
Provisional Applications (1)
Number Date Country
61485065 May 2011 US